$BIOX Cashflow Statement | Understand Stock

$BIOX

$0.24 +$0.03 (16.95%) Close

$BIOX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Jun 30, 2025	FY2024 12 months to Jun 30, 2024	FY2023 12 months to Jun 30, 2023	FY2022 12 months to Jun 30, 2022	FY2021 12 months to Jun 30, 2021
Cash and cash equivalents and restricted cash, beginning of period
Cash and cash equivalents and restricted cash, end of period
OPERATING ACTIVITIES
(Loss)/ Profit for the year
Adjustments to reconcile profit to net cash flows
Income tax
Financial results
Depreciation of property, plant and equipment
Amortization of intangible assets
Depreciation of leased assets
Transactional expenses
Share-based incentive and stock options
Share of profit or loss of joint ventures and associates
Loss of participation in joint ventures and associates
Gain from a bargain purchase
Provisions for contingencies
Allowance for impairment of trade debtors
Allowance for obsolescence
Initial recognition and changes in the fair value of biological assets
Changes in the net realizable value of agricultural products after harvest
Gain on sale of equipment and intangible assets
Working capital adjustments
Trade receivables
Other receivables
Income and minimum presumed income taxes
Inventories and biological assets
Trade and other payables
Employee benefits and social security
Deferred revenue and advances from customers
Income taxes paid
Government grants
Interest collected
Inflation effects on working capital adjustments

Net cash flows generated by operating activities
INVESTMENT ACTIVITIES
Proceeds from sale of property, plant and equipment
Investment in joint ventures and associates
Net cash received from business combination
Net loans granted to shareholders and other related parties
Proceeds from financial assets
Investment in financial assets
Purchase of property, plant and equipment
Capitalized development expenditures
Purchase of intangible assets
Net cash flows used by investing activities

FINANCING ACTIVITIES
Proceeds from borrowings
Repayment of borrowings and financed payments
Interest payments
Decrease in bank overdrafts and other short-term borrowings
Other financial payments
Acquisition of non-controlling interest in subsidiaries
Purchase of own shares
Leased assets payments
Warrants tender offer payments
Cash dividend distributed by subsidiary
Net cash flows (used by)/ generated by financing activities

Net (decrease)/ increase in cash and cash equivalents
Inflation effects on cash and cash equivalents
Cash and cash equivalents as of beginning of the year
Effect of exchange rate changes on cash and equivalents
Cash and cash equivalents as of the end of the year

Comments